Canada Biomedical Research Fund and Biosciences Research Infrastructure Fund—Stage 2: 1. Description
Through Canada’s Biomanufacturing and Life Sciences Strategy (the Strategy), the Government of Canada is investing more than $2.2 billion over seven years to continue growing a strong, competitive biomanufacturing and life sciences sector, and to ensure Canada is prepared for future pandemics by increasing domestic capacity through investments and partnerships to produce life-saving vaccines and therapeutics.
The Strategy includes the following foundational investments to help build Canada’s talent pipeline and research systems, as well as foster the growth of Canadian life sciences firms: Canada Biomedical Research Fund (CBRF), Biosciences Research Infrastructure Fund (BRIF), and Clinical Trials Fund.
The CBRF and BRIF are based on an ecosystem approach, designed to build on existing assets and infrastructure, and to forge partnerships across multiple sectors, including industry and government research facilities. To maximize impact and ensure investments complement and reinforce each other, the programs feature a two-stage, integrated competitive process, co-led by the Canada Foundation for Innovation (CFI) and the Tri-agency Institutional Programs Secretariat (TIPS) housed at the Social Sciences and Humanities Research Council (SSHRC):
- Stage 1: selection of research hubs
- Stage 2: eligible institutions submit partnered proposals for high risk and applied research, talent development and research infrastructure funding. Each proposal must be aligned with one of the hubs’ priorities, vision, and program of research, support pandemic preparedness and respond to emerging health threats.
- Date modified: